RLIP76 Targeted Therapy for Kidney Cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pharmaceutical Research

• Publication date

  2015-05-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s11095-015-1723-1PMID 26021465PMCID PMC5384263
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RLIP76 Blockade by siRNA Inhibits Proliferation, Enhances Apoptosis, and Suppresses Invasion in HT29 Colon Cancer Cells

  2015cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Knockdown of RLIP76 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to daunorubicin in U937 leukemia cells

  2014cited by this paper
• Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells

  2013cited by this paper
• Emerging treatments in lung cancer – targeting the RLIP76 molecular transporter

  2013cited by this paper
• RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis.

  2013cited by this paper
• RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization.

  2012cited by this paper
• State of the Science: An Update on Renal Cell Carcinoma

  2012cited by this paper
• Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse

  2012cited by this paper
• Targeting p53-Null Neuroblastomas through RLIP76

  2011cited by this paper
• Gastrointestinal stromal tumours: origin and molecular oncology

  2011cited by this paper
• Glutathione-Conjugate Transport by RLIP76 Is Required for Clathrin-Dependent Endocytosis and Chemical Carcinogenesis

  2011influential reference
• The Notch and TGF-β Signaling Pathways Contribute to the Aggressiveness of Clear Cell Renal Cell Carcinoma

  2011cited by this paper
• Molecular diagnosis and therapy of kidney cancer.

  2010cited by this paper
• RalBP1 is necessary for metastasis of human cancer cell lines.

  2010cited by this paper
• RLIP76: a versatile transporter and an emerging target for cancer therapy.

  2010cited by this paper
• Role of RLIP76 in doxorubicin resistance in lung cancer.

  2009cited by this paper
• Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer

  2009influential reference
• Functional reconstitution of RLIP76 catalyzing ATP-dependent transport of glutathione-conjugates.

  2009cited by this paper
• RLIP76: a target for kidney cancer therapy.

  2009influential reference
• Regression of prostate cancer xenografts by RLIP76 depletion.

  2009cited by this paper
• RLIP76: A novel glutathione-conjugate and multi-drug transporter.

  2009influential reference
• Resistance to targeted therapy in renal-cell carcinoma.

  2009cited by this paper
• RLIP76 in defense of radiation poisoning.

  2008influential reference
• The determination of glutathione-4-hydroxynonenal (GSHNE), E-4-hydroxynonenal (HNE), and E-1-hydroxynon-2-en-4-one (HNO) in mouse liver tissue by LC-ESI-MS

  2008cited by this paper
• The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer

  2008cited by this paper
• RLIP76 and Cancer

  2008influential reference
• Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo.

  2008cited by this paper
• Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

  2008cited by this paper
• Self-regulatory role of 4-hydroxynonenal in signaling for stress-induced programmed cell death.

  2008cited by this paper
• Hsf-1 and POB1 Induce Drug Sensitivity and Apoptosis by Inhibiting Ralbp1*

  2008influential reference
• Studying cytochrome P450 kinetics in drug metabolism.

  2008cited by this paper
• Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.

  2008cited by this paper
• Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges

  2008cited by this paper
• Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76

  2008influential reference
• Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer

  2007cited by this paper
• Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76).

  2007cited by this paper
• Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.

  2007cited by this paper
• Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27[kip1] enhancement, and disruption of binding to the extracellular matrix

  2007cited by this paper
• Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).

  2007cited by this paper
• Renal-cell carcinoma--molecular pathways and therapies.

  2007cited by this paper
• RALBP1/RLIP76 mediates multidrug resistance.

  2007cited by this paper
• Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy.

  2007cited by this paper
• Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference

  2007cited by this paper
• Genetic Basis of Cancer of the Kidney

  2006cited by this paper
• Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.

  2006cited by this paper
• Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma

  2006cited by this paper
• Glutathione-Conjugate Transport and Stress-Response Signaling: Role of RLIP76

  2006cited by this paper
• Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

  2006cited by this paper
• Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.

  2006cited by this paper
• The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy.

  2006cited by this paper
• Anti-CD26 Monoclonal Antibody–Mediated G1-S Arrest of Human Renal Clear Cell Carcinoma Caki-2 Is Associated with Retinoblastoma Substrate Dephosphorylation, Cyclin-Dependent Kinase 2 Reduction, p27kip1 Enhancement, and Disruption of Binding to the Extracellular Matrix

  2006cited by this paper
• mTOR and cancer: reason for dancing at the crossroads?

  2006cited by this paper
• Molecular targeting therapy for renal cell carcinoma

  2006cited by this paper
• Kinase inhibitors in the treatment of renal cell carcinoma.

  2006cited by this paper
• Three new drugs available to fight kidney cancer.

  2006cited by this paper
• Regression of melanoma in a murine model by RLIP76 depletion.

  2006cited by this paper
• Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

  2006cited by this paper
• Is a Major Determinant of Radiation Sensitivity

  2005influential reference
• The role of PKCα and RLIP76 in transport‐mediated doxorubicin‐resistance in lung cancer

  2005cited by this paper
• Renal-cell carcinoma.

  2005cited by this paper
• RLIP76 is a major determinant of radiation sensitivity.

  2005cited by this paper
• Raf kinase as a target for anticancer therapeutics

  2005cited by this paper
• RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer.

  2005cited by this paper
• Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin.

  2005cited by this paper
• RLIP76 (RALBP1)‐mediated transport of leukotriene C4 (LTC4) in cancer cells: Implications in drug resistance

  2004cited by this paper
• Genetic Basis of Cancer of the Kidney

  2004cited by this paper
• Identification of membrane-anchoring domains of RLIP76 using deletion mutant analyses.

  2004cited by this paper
• Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice.

  2004cited by this paper
• ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor–Extracellular Signal-Regulated Kinase Pathway

  2004cited by this paper
• Role of VHL gene mutation in human cancer.

  2004cited by this paper
• HSF-1 Interacts with Ral-binding Protein 1 in a Stress-responsive, Multiprotein Complex with HSP90 in Vivo *

  2003influential reference
• REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells

  2003cited by this paper
• Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): A novel link between G‐protein and tyrosine kinase signaling and drug resistance

  2003influential reference
• VHL and kidney cancer.

  2003cited by this paper
• RLIP, an Effector of the Ral GTPases, Is a Platform for Cdk1 to Phosphorylate Epsin during the Switch Off of Endocytosis in Mitosis*

  2003cited by this paper
• Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity.

  2003cited by this paper
• Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76.

  2003cited by this paper
• A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.

  2001cited by this paper
• RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor endocytosis.

  2000cited by this paper
• Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.

  2000cited by this paper
• Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin.

  2000cited by this paper
• Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein

  2000cited by this paper
• The multidrug resistance protein family.

  1999cited by this paper
• A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.

  1998cited by this paper
• An Eps Homology (EH) Domain Protein That Binds to the Ral-GTPase Target, RalBP1*

  1997cited by this paper
• Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein

  1997cited by this paper
• Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney.

  1996cited by this paper
• Bridging Ral GTPase to Rho Pathways

  1995cited by this paper
• A putative effector of Ral has homology to Rho/Rac GTPase activating proteins.

  1995cited by this paper
• A putative effector of Ral has homology to Rho/Rac GTPase activating proteins.

  1995cited by this paper
• The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.

  1995influential reference
• Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein.

  1994cited by this paper
• Interactions of glutathione S-transferase-pi with ethacrynic acid and its glutathione conjugate.

  1993cited by this paper
• Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes.

  1991cited by this paper
• Cancer statistics

  1989cited by this paper
• Renal cell carcinoma.

  1956cited by this paper
• Identification and Characterization of Ral-Binding Protein 1, a Potential Downstream Target of Ral GTPases

  year unknowncited by this paper

• Rlip76 in ageing and Alzheimer's disease: Focus on oxidative stress and mitochondrial mechanisms.

  2024cites this paper
• Pterostilbene and 6-shogaol exhibit inhibitory effects on sunitinib resistance and motility by suppressing the RLIP76-initiated Ras/ERK and Akt/mTOR pathways in renal cancer cells.

  2024cites this paper
• The Underestimated Role of the p53 Pathway in Renal Cancer

  2022cites this paper
• Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis

  2021cites this paper
• Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in Preclinical In Vivo Models.

  2021cites this paper
• Anticancer Activity of Ω-6 Fatty Acids through Increased 4-HNE in Breast Cancer Cells

  2021cites this paper
• Glutathione: subcellular distribution and membrane transport 1.

  2019cites this paper
• RLIP inhibition suppresses breast-to-lung metastasis.

  2019cites this paper
• Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities

  2019cites this paper
• The mercapturic acid pathway

  2019cites this paper
• RLIP76 decreases apoptosis through Akt/mTOR signaling pathway in gastric cancer

  2016cites this paper
• Downregulation of RLIP76 is associated with vincristine resistance in human colorectal cancer HCT-8/VCR cells.

  2016cites this paper